RxDoctor Payments Data

Gladys Baksh, NP

Adult Health · Hershey, PANPI 1336402353

Payments from drug & device makers

$701in general payments, 2019–2025

Across 13 payments — averaging $53.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$139
  • ZOLL Respicardia, Inc.$129
  • AstraZeneca$124
  • Abbott$109
  • Johnson & Johnson$93
  • Novartis$76
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$701 in reported general payments places this provider in the 60th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,312
Medicare patients
64
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan251$241,210
FarxigaDapagliflozin Propanediol136$110,003
JardianceEmpagliflozin102$87,264
EliquisApixaban36$33,167
Metoprolol Succinate188$3,214
Potassium Chloride67$1,341
Bumetanide39$1,112
Torsemide29$651
Spironolactone93$535
Furosemide113$412
Atorvastatin Calcium13$299
Valsartan12$215
Carvedilol20$137
Amiodarone Hcl11$116
Lisinopril14$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$76$241,210251 claims
AstraZenecaFarxiga$124$110,003136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →